The weekend protocol. 36-hour window means no timing pressure. Also available in daily low-dose (5mg) for continuous coverage. Doctor-supervised, discreetly delivered.
Tadalafil is distinguished by its extended duration of action compared to sildenafil. Its long half-life creates a sustained window of effectiveness, reducing timing anxiety and allowing for a more natural approach to sexual activity.
Tadalafil's bioavailability is not formally stated (due to IV insolubility) but oral absorption is extensive. The key pharmacokinetic feature is the long half-life (17.5 hours) — much longer than sildenafil (3–5h). This creates a unique "weekend pill" profile where one dose covers an extended window. Tmax ranges 0.5–6 hours (highly variable). Active metabolite methylcatechol contributes minimally to effects.
| Bioavailability | Unknown (IV insolubility prevents formal determination), but oral absorption extensive |
| Tmax (time to peak) | 0.5–6 hours (highly variable) |
| Elimination half-life | 17.5 hours (much longer than sildenafil!) |
| Duration of action | 36 hours at effective concentrations (therapeutic window extends far beyond half-life) |
| Volume of distribution | ~1.25 L/kg |
| Protein binding | ~94% — highly protein-bound |
| Metabolism | Hepatic: CYP3A4 (primary). Slower metabolism than sildenafil due to longer half-life. |
| Active metabolite | Methylcatechol (minimal activity, ~0.1% of parent potency) |
| Excretion | Fecal ~61%, renal ~36%. Minimal unchanged parent excreted. |
| Food effect | NO food effect — absorption is independent of meals. Can take anytime. |
Tadalafil offers two distinct dosing strategies: (1) Daily low-dose (5mg once daily) for continuous coverage, no timing required; or (2) As-needed higher-dose (10–20mg) before sexual activity with 36h efficacy window. Daily dosing is increasingly preferred as it removes timing anxiety and may improve overall endothelial function.
Tadalafil is extensively studied with dual FDA indications (ED and benign prostatic hyperplasia). Long half-life and daily dosing strategy add unique evidence base compared to on-demand PDE5 inhibitors. Emerging research suggests cardiovascular protective effects.
Tadalafil's side effect profile is similar to sildenafil at therapeutic doses, with one notable addition: back pain and myalgia (unique to tadalafil at ~6% incidence). This is attributed to PDE11 cross-reactivity in skeletal muscle. Most effects are mild and dose-dependent.
Tadalafil is metabolized by CYP3A4 like sildenafil. Long half-life means CYP3A4 interactions have extended consequences — inhibitors accumulate tadalafil over days. Nitrates are absolute contraindication. Alpha-blockers require caution, especially with daily dosing.
Book a consultation with a licensed physician to discuss whether tadalafil is the right choice for you.